Invitation: Sobi's Q3 2024 report

Invitation: Sobi's Q3 2024 report. Swedish Orphan Biovitrum AB Sweden

before the conference call.

To participate in the conference call, please use the following dial-in details:
Sweden: [phone]
United Kingdom: [phone]
United States: [phone]
For other countries, please find the details here.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q3-2024-report,c4044905

The following files are available for download:

https://mb.cision.com/Main/14266/4044905/3030533.pdf

Invitation Sobiâ™'s Q3 2024 report

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q3-2024-report-302271453.html